Top

Published in:

01-04-2020 | Lung Cancer | Original Article

Silencing NID2 by DNA Hypermethylation Promotes Lung Cancer

Authors: Jianfeng Wang, Yan Zhao, Hongyan Xu, Jun Ma, Feihai Liang, Qingxu Zou, Fengwu Lin

Published in: Pathology & Oncology Research | Issue 2/2020

Abstract

To characterize the DNA methylation as well as exploring the relationship between NID2 methylation and the lung cancer development. Collecting chip data of 9 lung cancer samples and 11 adjacent normal samples from the Gene Expression Omnibus database. Tissues and cells NID2 gene methylation level was measured by methylation-specific PCR. NID2 mRNA level and protein level were validated by Real-Time PCR and Western blot separately. Functional study of lung cancer cells was performed with Cell Counting Kit-8 assay. Colony formation assay, transwell assay, wound healing assay and low cytometry were performed. Finally, NID2 tumorigenesis in vivo was tested in nude mice xenograft models. Microarray analysis outcome present NID2 hypermethylation status in lung cancer tissues. High methylation and low mRNA expression levels of NID2 were detected. After NID2 demethylation or overexpression in cancer cells, cell viability, proliferation, migration as well as invasion ability decreased. Nevertheless, a significant enhancement in apoptosis rate were observed. Overexpressing NID2 or demethylation in lung cancer cells inhibited the tumorigenesis of lung cancer in nude mice. The mRNA and protein level of NID2 in tumors obtained from nude mice xenograft were unanimous with the in vitro assays’ outcome, which significantly decreased after overexpressing NID2 or demethylation. NID2 methylation reduces its expression level and promotes the development of lung cancer.

Christopoulos P, Kirchner M, Bozorgmehr F, Endris V, Elsayed M, Budczies J, Ristau J, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Lasitschka F, Bischoff H, Sotillo R, Schirmacher P, Thomas M, Stenzinger A (2018) Identification of a highly lethal V3(+) TP53(+) subset in ALK(+) lung adenocarcinoma. Int J Cancer. https://doi.org/10.1002/ijc.31893 CrossRef

Morrow JD, Glass K, Cho MH, Hersh CP, Pinto-Plata V, Celli B, Marchetti N, Criner G, Bueno R, Washko G, Choi AMK, Quackenbush J, Silverman EK, DeMeo DL (2018) Human Lung DNA methylation quantitative trait loci Colocalize with chronic obstructive pulmonary disease genome-wide association loci. Am J Respir Crit Care Med 197(10):1275–1284. https://doi.org/10.1164/rccm.201707-1434OC CrossRefPubMedPubMedCentral

Chen WQ, Li H, Sun KX, Zheng RS, Zhang SW, Zeng HM, Zou XN, Gu XY, He J (2018) Report of Cancer incidence and mortality in China, 2014. Zhonghua zhong liu za zhi [Chinese journal of oncology] 40(1):5–13. https://doi.org/10.3760/cma.j.issn.0253-3766.2018.01.002 CrossRef

Hong QY, Wu GM, Qian GS, Hu CP, Zhou JY, Chen LA, Li WM, Li SY, Wang K, Wang Q, Zhang XJ, Li J, Gong X, Bai CX, Lung Cancer Group of Chinese Thoracic S, Chinese Alliance Against Lung C (2015) Prevention and management of lung cancer in China. Cancer 121 Suppl 17:3080–3088. https://doi.org/10.1002/cncr.29584 CrossRef

Vlahopoulos S, Adamaki M, Khoury N, Zoumpourlis V, Boldogh I (2018) Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer. Pharmacol Ther. https://doi.org/10.1016/j.pharmthera.2018.09.004 CrossRef

Feng X, Xie X, Zheng B, Peng C, Zhou H, Qin J (2018) The more potential performance of nidogen 2 methylation by tissue or plasma DNA over brichoalveolar lavage DNA in diagnosis of nonsmall cell lung cancer. J Cancer Res Ther 14(Supplement):S341–S346. https://doi.org/10.4103/0973-1482.235352 CrossRefPubMed

Risch A, Plass C (2008) Lung cancer epigenetics and genetics. Int J Cancer 123(1):1–7. https://doi.org/10.1002/ijc.23605 CrossRefPubMed

Schubeler D (2015) Function and information content of DNA methylation. Nature 517(7534):321–326. https://doi.org/10.1038/nature14192 CrossRefPubMed

Mehrmohamadi M, Mentch LK, Clark AG, Locasale JW (2016) Integrative modelling of tumour DNA methylation quantifies the contribution of metabolism. Nat Commun 7:13666. https://doi.org/10.1038/ncomms13666 CrossRefPubMedPubMedCentral

10.

Gut P, Verdin E (2013) The nexus of chromatin regulation and intermediary metabolism. Nature 502(7472):489–498. https://doi.org/10.1038/nature12752 CrossRefPubMed

11.

Locasale JW (2013) Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer 13(8):572–583. https://doi.org/10.1038/nrc3557 CrossRefPubMedPubMedCentral

12.

Mentch SJ, Mehrmohamadi M, Huang L, Liu X, Gupta D, Mattocks D, Gomez Padilla P, Ables G, Bamman MM, Thalacker-Mercer AE, Nichenametla SN, Locasale JW (2015) Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism. Cell Metab 22(5):861–873. https://doi.org/10.1016/j.cmet.2015.08.024 CrossRefPubMedPubMedCentral

13.

Anderson OS, Sant KE, Dolinoy DC (2012) Nutrition and epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation. J Nutr Biochem 23(8):853–859. https://doi.org/10.1016/j.jnutbio.2012.03.003 CrossRefPubMedPubMedCentral

14.

Berman BP, Weisenberger DJ, Aman JF, Hinoue T, Ramjan Z, Liu Y, Noushmehr H, Lange CP, van Dijk CM, Tollenaar RA, Van Den Berg D, Laird PW (2011) Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet 44(1):40–46. https://doi.org/10.1038/ng.969 CrossRefPubMedPubMedCentral

15.

Landau DA, Clement K, Ziller MJ, Boyle P, Fan J, Gu H, Stevenson K, Sougnez C, Wang L, Li S, Kotliar D, Zhang W, Ghandi M, Garraway L, Fernandes SM, Livak KJ, Gabriel S, Gnirke A, Lander ES, Brown JR, Neuberg D, Kharchenko PV, Hacohen N, Getz G, Meissner A, Wu CJ (2014) Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell 26(6):813–825. https://doi.org/10.1016/j.ccell.2014.10.012 CrossRefPubMedPubMedCentral

16.

Geng J, Sun J, Lin Q, Gu J, Zhao Y, Zhang H, Feng X, He Y, Wang W, Zhou X, Yu J (2012) Methylation status of NEUROG2 and NID2 improves the diagnosis of stage I NSCLC. Oncol Lett 3(4):901–906. https://doi.org/10.3892/ol.2012.587 CrossRefPubMedPubMedCentral

17.

Vasiljevic N, Ahmad AS, Beesley C, Thorat MA, Fisher G, Berney DM, Moller H, Yu Y, Lu YJ, Cuzick J, Foster CS, Lorincz AT (2013) Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. Prostate Cancer Prostatic Dis 16(1):35–40. https://doi.org/10.1038/pcan.2012.47 CrossRefPubMed

18.

Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, Hubank MJ, Ahmed A, Masters JR (2007) Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 26(45):6560–6565. https://doi.org/10.1038/sj.onc.1210472 CrossRefPubMed

19.

Chai AW, Cheung AK, Dai W, Ko JM, Ip JC, Chan KW, Kwong DL, Ng WT, Lee AW, Ngan RK, Yau CC, Tung SY, Lee VH, Lam AK, Pillai S, Law S, Lung ML (2016) Metastasis-suppressing NID2, an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma. Oncotarget 7(48):78859–78871. https://doi.org/10.18632/oncotarget.12889 CrossRefPubMedPubMedCentral

20.

Kohfeldt E, Sasaki T, Gohring W, Timpl R (1998) Nidogen-2: a new basement membrane protein with diverse binding properties. J Mol Biol 282(1):99–109. https://doi.org/10.1006/jmbi.1998.2004 CrossRefPubMed

21.

Mokkapati S, Bechtel M, Reibetanz M, Miosge N, Nischt R (2012) Absence of the basement membrane component nidogen 2, but not of nidogen 1, results in increased lung metastasis in mice. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 60(4):280–289. https://doi.org/10.1369/0022155412436586 CrossRef

22.

Ulazzi L, Sabbioni S, Miotto E, Veronese A, Angusti A, Gafa R, Manfredini S, Farinati F, Sasaki T, Lanza G, Negrini M (2007) Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. Mol Cancer 6:17. https://doi.org/10.1186/1476-4598-6-17 CrossRefPubMedPubMedCentral

23.

Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59(1):67–70PubMed

24.

Li B, Lu Q, Song ZG, Yang L, Jin H, Li ZG, Zhao TJ, Bai YF, Zhu J, Chen HZ, Xu ZY (2013) Functional analysis of DNA methylation in lung cancer. Eur Rev Med Pharmacol Sci 17(9):1191–1197PubMed

25.

Hsiao SH, Huang TH, Leu YW (2009) Excavating relics of DNA methylation changes during the development of neoplasia. Semin Cancer Biol 19(3):198–208. https://doi.org/10.1016/j.semcancer.2009.02.015 CrossRefPubMed

26.

Timpl R, Brown JC (1996) Supramolecular assembly of basement membranes. BioEssays : news and reviews in molecular, cellular and developmental biology 18(2):123–132. https://doi.org/10.1002/bies.950180208 CrossRef

27.

Dong LJ, Hsieh JC, Chung AE (1995) Two distinct cell attachment sites in entactin are revealed by amino acid substitutions and deletion of the RGD sequence in the cysteine-rich epidermal growth factor repeat 2. J Biol Chem 270(26):15838–15843CrossRef

28.

Wu C, Chung AE, McDonald JA (1995) A novel role for alpha 3 beta 1 integrins in extracellular matrix assembly. J Cell Sci 108(Pt 6):2511–2523PubMed

29.

Dedhar S, Jewell K, Rojiani M, Gray V (1992) The receptor for the basement membrane glycoprotein entactin is the integrin alpha 3/beta 1. J Biol Chem 267(26):18908–18914PubMed

Title: Silencing NID2 by DNA Hypermethylation Promotes Lung Cancer
Authors: Jianfeng Wang
Yan Zhao
Hongyan Xu
Jun Ma
Feihai Liang
Qingxu Zou
Fengwu Lin
Publication date: 01-04-2020
Publisher: Springer Netherlands
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Published in: Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00609-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients

Differential Analysis of lncRNA, miRNA and mRNA Expression Profiles and the Prognostic Value of lncRNA in Esophageal Cancer

TRIM72 Immunohistochemical Expression Can Predict Relapse in Colorectal Carcinoma

Analysis of Promoter Mutation in Long Non-coding RNA NEAT1 in Acute Leukemias

Comparison of CDH1 Gene Hypermethylation Status in Blood and Serum among Gastric Cancer Patients

The Impact of MicroRNA-133a on Prognosis and Clinicopathological Parameters for Digestive System Cancers: a Comprehensive Study Based on Meta-Analysis and TCGA Database

Keynote webinar | Spotlight on antibody–drug conjugates in cancer